Skip to content

Camel-IDS appoints Ruggero Della Bitta MD, PhD, as Chief Medical Officer

Brussels (Belgium), 8 October 2019

Camel-IDS, a privately-held biotechnology company developing novel radiopharmaceuticals, today announced the appointment of Ruggero Della Bitta MD, PhD, as Chief Medical Officer of Camel-IDS, effective October 1, 2019.

Dr. Della Bitta has more than 25 years of experience in oncology drug development, leading to the approval of several cancer medicines. Most recently, Dr. Della Bitta was VP Product Development Oncology, franchise lead -antiangiogenesis and cancer immunotherapy- at Roche/Genentech in Basel. He also served as Global Head of Clinical Evaluation in the Roche Partneringdivision, contributing to in-licensing of oncology assets.

From 2004 to 2011, Dr. Della Bitta was VP Oncology New Therapies for Merck-Serono, based in Geneva. Earlier, Dr. Della Bitta held positions of increasing responsibility in oncology clinical development and general management – Phases I-III at Chiron in US and EU and General Manager Italy in Quintiles/Iqvia.

Prior to his industry experience, Dr. Della Bitta worked in the Medical Faculty of the Division of Internal Medicine and Hematology at the University of Ancona in Italy and at the Cancer Institute in Milano.

Dr. Della Bitta is board certified in Internal Medicine and Hematology.

About Camel-IDS

Camel-IDS is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid single domain antibody fragments (sdAb) labeled with radioisotopes. The Company is advancing its lead product CAM-H2 towards a phase I/II trial targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. Breast cancer patients with tumors that overexpress HER2, a growth-promoting protein, can benefit from effective targeted treatments today, yet have a poor prognosis when the cancer progresses towards the brain. Camel-IDS’ lead program CAM-H2 aims to effectively irradiate brain lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of camelid derived single domain antibodies linked to radionuclides. The company’s technology platform also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a high therapeutic dose for treatment.


Camel-IDS, a VUB spin-off company incorporated in 2014, secured EUR 37m in a Series A investment round in November 2018, led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel), BioMedPartners (Switzerland) and existing investors. For more information, please visit


For further information, please contact:
Ruth Devenyns, CEO Camel-IDS
+32 496 57 90 32


Source: Camel-IDS Camel-IDS 20191008 PR